Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2018

Geoffrey W Coombs, Denise A Daley, Shakeel Mowlaboccus, Yung Thin Lee and Stanley Pang, on behalf of the Australian Group on Antimicrobial Resistance

# Abstract

From 1 January to 31 December 2018, thirty-six institutions around Australia participated in the Australian Enterococcal Sepsis Outcome Programme (AESOP). The aim of AESOP 2018 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to characterise the molecular epidemiology of the E. faecium isolates. Of the 1,248 unique episodes of bacteraemia investigated, 93.5% were caused by either E. faecalis (54.2%) or E. faecium (39.3%). Ampicillin resistance was not detected in E. faecalis but was detected in 89.4% of E. faecium. Vancomycin non-susceptibility was not detected in E. faecalis but was reported in 45.0% of E. faecium. Overall 49.3% of E. faecium isolates harboured vanA or vanB genes. Of the vanA/vanB positive E. faecium isolates, 52.9% harboured vanA genes and 46.2% vanB genes; 0.8% harboured both vanA and vanB genes. The percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia is substantially higher than that seen in most European countries. E. faecium consisted of 59 multilocus sequence types (STs) of which 74.4% of isolates were classified into six major STs containing ten or more isolates. All major STs belong to clonal cluster (CC) 17, a major hospital-adapted polyclonal E. faecium cluster. The predominant STs (ST17, ST1424, ST796, ST80, ST1421, and ST262) were found across most regions of Australia. The most predominant clone was ST17 which was identified in all regions except the Australian Capital Territory and the Northern Territory. Overall, 55.8% of isolates belonging to the six predominant STs harboured vanA or vanB genes. The AESOP 2018 study has shown that enterococcal bacteraemias in Australia are frequently caused by polyclonal ampicillin-resistant high-level gentamicin-resistant vanA- or vanB-harbouring E. faecium which have limited treatment options.

Keywords: Australian Group on Antimicrobial Resistance (AGAR); antimicrobial resistance surveillance; Enterococcus faecium; Enterococcus faecalis; vancomycin resistant enterococci (VRE); bacteraemia

# Background

Globally, enterococci are thought to account for approximately 10% of all bacteraemias, and in North America and Europe are the fourth and fifth leading cause of sepsis respectively.1,2 Although in the 1970s healthcare-associated enterococcal infections were primarily due to Enterococcus faecalis, there has been a steadily-increasing prevalence of E. faecium nosocomial infections.3–5 Worldwide, the increase in nosocomial E. faecium infections has primarily been due to the expansion of polyclonal hospital-adapted clonal complex (CC) 17 strains. While innately resistant to many classes of antibiotics, E. faecium has demonstrated a remarkable capacity to evolve new antimicrobial resistances. In 2009 the Infectious Diseases Society of America highlighted E. faecium as one of the key problem bacteria or ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens requiring new therapies.6

The Australian Group on Antimicrobial Resistance (AGAR) is a network of laboratories, located across Australia, which commenced surveillance of antimicrobial resistance in Enterococcus species in 1995.7 In 2011 AGAR commenced the Australian Enterococcal Sepsis Outcome Programme (AESOP).8,9 The objective of AESOP 2018 was to determine the proportion of E. faecalis and E. faecium bacteraemia isolates demonstrating antimicrobial resistance with particular emphasis on:

1. assessing susceptibility to ampicillin
2. assessing susceptibility to glycopeptides
3. molecular epidemiology of E. faecium

# Methodology

## Participants

Thirty-six laboratories from all eight Australian states and mainland territories.

## Collection period

From 1 January to 31 December 2018, the 36 laboratories collected all enterococcal species isolated from blood cultures. Enterococci with the same species and antimicrobial susceptibility profiles isolated from a patient’s blood culture within 14 days of the first positive culture were excluded. A new enterococcal sepsis episode in the same patient was recorded if it was confirmed by a further culture of blood taken more than 14 days after the initial positive culture. Data were collected on age, sex, date of admission and discharge (if admitted), and mortality at seven and 30 days from date of blood culture collection. To avoid interpretive bias, no attempt was made to assign attributable mortality. Each episode of bacteraemia was designated as “hospital-onset” if the first positive blood culture(s) in an episode was collected > 48 hours after admission.

## Laboratory testing

Enterococcal isolates were identified to the species level by the participating laboratories using one of the following methods: API 20S (bioMérieux, France), API ID32Strep (bioMérieux), Vitek2® (bioMérieux), Phoenix™ (Becton Dickinson, USA), matrix-assisted laser desorption ionization (MALDI) Biotyper (Bruker Daltonics, USA), Vitek-MS (bioMérieux), polymerase chain reaction (PCR), or conventional biochemical tests. Antimicrobial susceptibility testing was performed by using the Vitek2 or Phoenix automated microbiology systems according to the manufacturer’s instructions. Minimum inhibitory concentration (MIC) data and isolates were referred to the Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory at Murdoch University. Clinical and Laboratory Standards Institute (CLSI)10 and European Committee on Antimicrobial Susceptibility Testing (EUCAST)11 breakpoints were utilised for interpretation.Isolates with either a resistant or an intermediate category were classified as non-susceptible. Linezolid and daptomycin non-susceptible isolates and vancomycin-susceptible isolates which harboured vanA or vanB genes were retested by Etest® (bioMérieux) using the Mueller-Hinton agar recommended by the manufacturer. The control strain used was E. faecalis ATCC® 29212. Molecular testing was performed by whole genome sequencing (WGS) using the NextSeq® platform (Illumina, San Diego, USA). Sequencing results were analysed using the Nullarbor pipeline.12

A chi-squared test for comparison of two proportions was performed and 95% confidence intervals (95% CI) were determined using MedCalc for Windows, version 12.7 (MedCalc Software, Ostend Belgium).

Approval to conduct the prospective data collection was given by the research ethics committee associated with each participating laboratory.

# Results

From 1 January to 31 December 2018, a total of 1,248 unique episodes of enterococcal bacteraemia were identified. Although nine Enterococcus species were identified, 54.2% (676 isolates) were E. faecalis and 39.3% (491 isolates) were E. faecium. Eighty-one enterococci were identified either as E. gallinarum (29 isolates), E. casseliflavus (21 isolates), E. avium (18 isolates), E. hirae (6 isolates), E. raffinosis (3 isolates) E. durans (3 isolates), or Enterococcus species (unidentified) (1 isolate).

A significant imbalance was seen in patient sex (p < 0.0001), with 799 (64.0%) being male (95% CI, 61.3–66.7). The average age of patients was 64 years ranging from 0 to 107 years with a median age of 68 years. The majority of episodes, 53.5% (668/1,248), were community-onset (95% CI, 50.7–56.3). However, a significant difference (p < 0.0001) in place of onset was seen between E. faecium and E. faecalis, with only 30.8% (95% CI, 26.7–35.1) of E. faecium episodes being community-onset compared to 68.2% (95% CI, 64.5–71.7) for E. faecalis. All-cause mortality at 30 days where data was known was 19.7% (95% CI, 17.3–22.3). There was a significant difference (p < 0.0001) in mortality between E. faecalis and E. faecium episodes, 14.7% vs 27.2% respectively, but not between vancomycin-susceptible and vancomycin non-susceptible E. faecium episodes, 24.5% vs 30.1% respectively (p = 0.2).

## *E. faecalis* phenotypic susceptibility results

Apart from erythromycin, tetracycline, ciprofloxacin and high-level gentamicin, acquired resistance was rare amongst E. faecalis (Table 1). Ampicillin and vancomycin resistance was not detected. Forty-seven (7.0%) E. faecalis were initially reported as linezolid non-susceptible (CLSI breakpoint > 2 mg/L). However by Etest®, 43 of the 47 isolates had a linezolid MIC of ≤ 2 mg/L and were therefore considered linezolid susceptible. Two of the remaining four isolates, with MICs of 3 mg/L, although non-susceptible by CLSI guidelines, were considered susceptible by EUCAST guidelines. The remaining two isolates with MICs of 8 mg/L were non-susceptible by both guidelines. Using WGS, both isolates contained the optrA gene which is known to confer linezolid resistance.

Table 1: The number and proportion of *E. faecalis* isolates non-susceptible to ampicillin and the non-β-lactam antimicrobials, Australia, 2018

| Antimicrobial | Tested | Breakpoint (mg/L) | Non-susceptible |
| --- | --- | --- | --- |
| n | % |
| Ampicillin | 675 | 8a | 0 | 0 |
| > 4b | 0 | 0 |
| Vancomycin | 675 | > 4c | 0 | 0 |
| Erythromycin | 560 | > 0.5a | 499 | 89.1 |
| Tetracycline/doxycycline | 504 | > 4a | 377 | 74.8 |
| Ciprofloxacin | 548 | > 1a | 71 | 13.0 |
| > 4b | 54 | 9.9 |
| Daptomycin | 674 | > 4a | 2 | 0.3 |
| Teicoplanin | 676 | > 8a | 0 | 0 |
| > 2b | 2 | 0.3 |
| Linezolid | 675 | > 2a | 5 | 0.7 |
| > 4b | 2 | 0.3 |
| Nitrofurantoin | 668 | > 32a | 10 | 1.5 |
| > 64b | 3 | 0.4 |
| High-level gentamicin | 602 | > 128b | 135 | 22.4 |

a CLSI non-susceptible breakpoint

b EUCAST non-susceptible breakpoint

c CLSI and EUCAST non-susceptible breakpoint

Seven isolates were initially reported as daptomycin non-susceptible (> 4 mg/L). However by Etest®, five of the isolates had daptomycin MICs of ≤ 4 mg/L and therefore were considered susceptible. The remaining two isolates were confirmed to have a daptomycin MIC of 6 mg/L, however no known single nucleotide mutations were identified using WGS.

## *E. faecium* phenotypic susceptibility results

The majority of E. faecium isolates were non-susceptible to multiple antimicrobials (Table 2). Most isolates were non-susceptible to ampicillin, erythromycin, tetracycline, ciprofloxacin, nitrofurantoin and high-level gentamicin. Overall, 221 (45.0%) were phenotypically vancomycin non-susceptible (MIC > 4 mg/L). Ninety-five (19.3%) and 102 (20.8%) isolates were teicoplanin non-susceptible by CLSI and EUCAST guidelines respectively. Sixteen (3.3%) isolates were initially reported as linezolid non-susceptible (CLSI breakpoint > 2 mg/L). However by Etest®, 13 of the 16 isolates had a linezolid MIC of ≤ 2 mg/L and therefore were considered susceptible. Two isolates had MICs of 12 and 64 mg/L and were non-susceptible by both guidelines, however no known single-nucleotide mutations were identified by WGS. One isolate was not available for confirmation.

Table 2: The number and proportion of *E. faecium* isolates non-susceptible to ampicillin and the non-β-lactam antimicrobials, Australia, 2018

| Antimicrobial | Tested | Breakpoint (mg/L) | Non-susceptible |
| --- | --- | --- | --- |
| n | % |
| Ampicillin | 491 | > 8a | 439 | 89.4 |
| > 4b | 440 | 89.6 |
| Vancomycin | 481 | > 4c | 221 | 45.0 |
| Erythromycin | 437 | > 0.5a | 410 | 93.8 |
| Tetracycline/doxycycline | 408 | > 4a | 256 | 62.7 |
| Ciprofloxacin | 390 | > 1a | 355 | 91.0 |
| > 4b | 339 | 86.9 |
| Teicoplanin | 491 | > 8a | 95 | 19.3 |
| > 2b | 102 | 20.8 |
| Linezolid | 481 | > 2a | 4 | 0.8 |
| > 4b | 2 | 0.4 |
| Nitrofurantoin | 453 | > 32a | 392 | 86.5 |
| > 64b | 190 | 41.9 |
| High-level gentamicin | 418 | > 128b | 179 | 42.8 |

a CLSI non-susceptible breakpoint

b EUCAST non-susceptible breakpoint

c CLSI and EUCAST non-susceptible breakpoint

## Genotypic vancomycin susceptibility results

vanA/vanB PCR results were available for 346 of the 676 E. faecalis isolates. Neither vanA nor vanB was detected. WGS was not performed on the E. faecalis isolates.

The presence of vanA/vanB genes was determined by PCR or WGS on 483 of the 491 E. faecium isolates. Overall, 238 (49.3%) of the 483 isolates harboured a vanA and/or vanB gene. A total of 116 of the vancomycin non-susceptible E. faecium isolates harboured vanA (Vitek® vancomycin MIC > 4 mg/L). A further 102 E. faecium vancomycin non-susceptible isolates harboured vanB. Two isolates harboured both vanA and vanB genes. Eighteen vancomycin-susceptible E. faecium isolates harboured vanA or vanB genes. Ten of these isolates harboured vanA (Vitek® vancomycin MIC ≤ 0.5 mg/L [8 isolates], MIC = 1 mg/L [1 isolate], MIC = 2 mg/L [1 isolate], teicoplanin ≤ 1 mg/L [10 isolates]). Eight isolates harboured vanB (Vitek® vancomycin MIC ≤ 0.5 mg/L [7 isolates] and 4 mg/L [1 isolate]).

## *E. faecium* molecular epidemiology

Of the 491 episodes, 465 E. faecium isolates were available for typing by WGS. The 465 isolates were classified into 59 sequence types (STs) including six STs with 10 or more isolates (Table 3). Of the 53 STs with < 10 isolates, 33 had only one isolate. Overall 346 (74.4%) of the 465 isolates were grouped into the six major STs. Using eBURST, all major STs were grouped into CC 17.

Table 3: The number and proportion of major *Enterococcus faecium* sequence types, Australia, 2018, by region

| ST | ACT | NSW | NT | Qld | SA | Tas | Vic | WA | Aus |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| ST17 | – | – | 10 | 7.2% | – | – | 31 | 58.5% | 8 | 21.1% | 3 | 13.0% | 12 | 9.8% | 24 | 46.2% | 88 | 18.9% |
| ST1424 | 9 | 36.0% | 53 | 38.1% | – | – | 3 | 5.7% | 1 | 2.6% | 5 | 21.7% | 2 | 1.6% | – | – | 73 | 15.7% |
| ST796 | – | – | 2 | 1.4% | 1 | 8.3% | – | – | 3 | 7.9% | 8 | 34.8% | 49 | 39.8% | 1 | 1.9% | 64 | 13.8% |
| ST80 | 4 | 16.0% | 12 | 8.6% | 2 | 16.7% | 3 | 5.7% | 5 | 13.2% | – | – | 9 | 7.3% | 20 | 38.5% | 54 | 11.8% |
| ST1421 | 8 | 32.0% | 30 | 21.6% | – | – | 1 | 1.9% | – | – | 1 | 4.3% | 15 | 12.2% | – | – | 55 | 11.8% |
| ST262 | 1 | 4.0% | – | – | – | – | – | – | 8 | 21.1% | – | – | 1 | 0.8% | 1 | 1.9% | 11 | 2.4% |
| Other | 3 | 12.0% | 32 | 23.0% | 9 | 75.0% | 15 | 28.3% | 13 | 34.2% | 6 | 26.1% | 35 | 28.5% | 6 | 11.5% | 119 | 25.6% |
| **Total** | **25** | **100.0%** | **139** | **100.0%** | **12** | **100.0%** | **53** | **100.0%** | **38** | **100.0%** | **23** | **100.0%** | **123** | **100.0%** | **52** | **100.0%** | **465** | **100.0%** |

ACT = Australian Capital Territory; NSW = New South Wales; NT = Northern Territory; Qld = Queensland; SA = South Australia; Tas = Tasmania; Vic = Victoria; WA = Western Australia; Aus = Australia

Geographical distribution of the STs varied (Table 3). For the six major STs, ST17 (88 isolates) was identified in all regions except the Australian Capital Territory and the Northern Territory; ST1424 (73 isolates) in all regions except the Northern Territory and Western Australia; ST796 (64 isolates) in all regions except the Australian Capital Territory and Queensland; ST80 (55 isolates) in all regions except Tasmania; ST1421 (55 isolates) in all regions except the Northern Territory, South Australia and Western Australia and ST262 (11 isolates) in all regions except New South Wales, the Northern Territory, South Australia and Western Australia.

The vanA gene was detected in four major STs (114 isolates, ST1424, ST1421, ST80 and ST262); vanB was detected in five major STs (77 isolates, ST796, ST17, ST80, ST262 and ST1424) (Table 4). One ST796 and one ST1421 isolate harboured both vanA and vanB genes. Five minor STs (six isolates) harboured vanA genes and seven minor STs (thirty isolates) harboured vanB genes.

Table 4: The number and proportion of major *Enterococcus faecium* sequence types harbouring *vanA*/*vanB* genes, Australia, 2018

| ST | n | *vanA* | *vanB* | *vanA* and *vanB* | Not detected |
| --- | --- | --- | --- | --- | --- |
| n | % | n | % | n | % | n | % |
| ST17 | 88 | – | – | 7 | 8.0% | – | – | 81 | 92.0% |
| ST1424 | 73 | 53 | 72.6% | 2 | 2.7% | – | – | 18 | 24.7% |
| ST796 | 64 | – | – | 62 | 96.9% | 1 | 1.6% | 1 | 1.6% |
| ST80 | 55 | 12 | 21.8% | 3 | 5.5% | – | – | 40 | 72.7% |
| ST1421 | 55 | 45 | 81.8% | – | – | 1 | 1.8% | 9 | 16.4% |
| ST262 | 11 | 4 | 36.4% | 3 | 27.3% | – | – | 4 | 36.4% |
| Other | 119 | 6 | 5.0% | 30 | 25.2% | – | – | 83 | 69.7% |
| **Total** | **465** | **120** | **25.8%** | **107** | **23.0%** | **2** | **0.4%** | **236** | **50.8%** |

# Discussion

Enterococci are intrinsically resistant to a broad range of antimicrobials including the cephalosporins and sulphonamides. By their ability to acquire additional resistance through the transfer of plasmids and transposons, and to disseminate easily in the hospital environment, enterococci have become difficult to treat and provide major infection control challenges.

As the AGAR programs are similar to those conducted in Europe, comparison of Australian antimicrobial resistance data with other countries is possible.

In the 2018 European Centre for Disease Prevention and Control (ECDC) enterococci surveillance program, the European Union/European Economic Area (EU/EEA) population-weighted mean percentage of E. faecium resistant to vancomycin was 17.3% (95% CI, 17–18), which represents a substantial increase from 2014 when the percentage was 10.4%. The national percentages ranged from 0.0% in Iceland (95% CI, 0–21), Luxembourg (95% CI, 0–12), and Slovenia (95% CI, 0–3) to 59.1% (95% CI, 43–74) in Cyprus.13

In AESOP 2018, 39.3% of enterococcal bacteraemia were due to E. faecium, of which 45.0% (95% CI, 42.2–47.8) were phenotypically vancomycin non-susceptible by Vitek2® or Phoenix™. However 49.3% of E. faecium isolates tested (238/483) harboured vanA/vanB genes, of which 53.8% were vanA. Overall, 26.1% (126/483) of E. faecium isolates harboured the vanA gene. There has been a substantial increase in vanA E. faecium in Australia over the AGAR surveys 2013 to 2018from 6.2% to 26.1% in 2018.14–18 The majority of E. faecium isolates were also non-susceptible to multiple antimicrobials including ampicillin, erythromycin, tetracycline, ciprofloxacin and high-level gentamicin. The AESOP surveys confirm that the incidence of vancomycin-resistant E. faecium bacteraemia in Australia is a substantial problem.

Eight (7.3%) of the 110 vanB E. faecium and ten (7.9%) of the 126 vanA E. faecium isolates had a vancomycin MIC at or below the CLSI and the EUCAST susceptible breakpoint (≤ 4 mg/L) and therefore would not have been identified using routine phenotypic antimicrobial susceptibility methods.

By WGS, E. faecium was shown to be very polyclonal, consistent with the known plasticity of the enterococcal genome. The six major E. faecium STs form part of CC 17, a global hospital-derived lineage that has successfully adapted to hospital environments. The CC 17 lineage is characteristically ampicillin and quinolone resistant and subsequent acquisition of vanA- or vanB-containing transposons by horizontal transfer in CC 17 clones has resulted in VRE with pandemic potential.

In AESOP 2018, six E. faecium STs predominated: ST17 (of which 8.0% of isolates harboured vanB genes); ST1424 (72.6% vanA, 2.7% vanB); ST796 (0% vanA, 96.9% vanB,1.6% vanA and vanB ); ST1421 (81.8% vanA, 0% vanB, 1.8% vanA and vanB), ST80 (21.8% vanA, 5.5% vanB), and ST262 (36.4% vanA, 27.3% vanB).

# Conclusions

The AESOP 2018 study has shown that, although predominately caused by E. faecalis, enterococcal bacteraemia in Australia is frequently caused by ampicillin-resistant, high-level gentamicin-resistant, vancomycin-resistant E. faecium. Furthermore, the percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia is notably higher than that seen in almost all European countries. While the vanB operon was the predominant genotype in Australia, in 2018 52.8% of E. faecium harboured the vanA gene. In addition to being a substantial cause of healthcare-associated sepsis, the emergence of multiple multi-resistant hospital-adapted E. faecium strains has become a major infection control issue in Australian hospitals. Ongoing studies on the enterococcal genome will contribute to our understanding of the rapid and ongoing evolution of enterococci in the hospital environment and will assist in preventing their nosocomial transmission.

# Acknowledgments

This study was funded by a grant from the Australian Commission on Safety and Quality in Healthcare.

Members of the AGAR in 2018 were:

## Australian Capital Territory

Peter Collignon and Susan Bradbury, Canberra Hospital

## New South Wales

Thomas Gottlieb and Steven Siarakas, Concord Hospital

James Branley and Donna Barbaro, Nepean Hospital

Peter Huntington, Royal North Shore Hospital

Sebastiaan van Hal and Alicia Beukers, Royal Prince Alfred Hospital

Jon Iredell and Andrew Ginn, Westmead Hospital

Rod Givney and Kimberly Ross, John Hunter Hospital

Peter Newton and Melissa Hoddle, Wollongong Hospital

Jock Harkness and David Lorenz, St Vincent’s Hospital

## Northern Territory

Rob Baird and Jann Hennessy, Royal Darwin Hospital

James McLeod, Alice Springs Hospital

## Queensland

Enzo Binotto and Bronwyn Thomsett, Pathology Queensland Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology Queensland Central Laboratory, Royal Brisbane and Women’s Hospital

Petra Derrington and Cheryl Curtis, Pathology Queensland Gold Coast Hospital

Robert Horvath and Laura Martin, Pathology Queensland Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology Queensland Princess Alexandra Hospital

Jennifer Robson and Georgia Peachey, Sullivan Nicolaides Pathology, Greenslopes Hospital

Clare Nourse, Lady Cilento Children’s Hospital

## South Australia

Kelly Papanaoum and Xiao Ming Chen, SA Pathology (Flinders Medical Centre)

Morgyn Warner and Kija Smith, SA Pathology (Royal Adelaide Hospital and Women’s and Children’s Hospital)

## Tasmania

Louise Cooley and David Jones, Royal Hobart Hospital

Pankaja Kalukottege and Kathy Wilcox, Launceston General Hospital

## Victoria

Denis Spelman and Chris Lee, Alfred Hospital

Marcel Leroi and Elizabeth Grabsch, Austin Health

Tony Korman and Despina Kotsanas, Monash Medical Centre and Monash Children’s Hospital

Andrew Daley and Gena Gonis, Royal Women’s and Children’s Hospital

Mary Jo Waters and Lisa Brenton, St Vincent’s Hospital

## Western Australia

David McGechie and Denise Daley, PathWest Laboratory Medicine – WA Fiona Stanley Hospital

Ronan Murray and Jacinta Bowman, PathWest Laboratory Medicine – WA Sir Charles Gairdner Hospital

Michael Leung, PathWest Laboratory Medicine – Northwest WA

Owen Robinson and Geoffrey Coombs, PathWest Laboratory Medicine – WA Royal Perth Hospital

Sudha Pottumarthy-Boddu and Fay Kappler, Australian Clinical Laboratories, St John of God Hospital, Murdoch

Shalinie Perera and Ian Meyer, Western Diagnostic Pathology, Joondalup Hospital

Christopher Blyth, Princess Margaret Hospital for Children

# Author details

Prof Geoffrey W Coombs,1,2 Ms Denise A Daley,2,3 Dr Shakeel Mowlaboccus,1 Ms Yung Thin Lee,1 Dr Stanley Pang,1,2

on behalf of the Australian Group on Antimicrobial Resistance.

1. Antimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia
2. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
3. Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

## Corresponding author

Prof Geoffrey Coombs

Antimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia

Telephone: +61 8 6152 2397

Email: g.coombs@murdoch.edu.au

# References

1. Pinholt M, Ostergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect. 2014;20(2):145–51.
2. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163–70.
3. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990;3(1):46–65.
4. Simonsen GS, Småbrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. J Antimicrob Chemother. 2003;51(2):323–31.
5. Treitman AN, Yarnold PR, Warren J, Noskin GA. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol. 2005;43(1):462–3.
6. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.
7. Christiansen KJ, Turnidge JD, Bell JM, George NM, Pearson JC, Australian Group on Antimicrobial Resistance. Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell Q Rep. 2007;31(4):392–7.
8. Coombs GW, Daley D, Pearson JC, Ingram PR. A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia. Pathology. 2014;46(1):73–5.
9. Coombs GW, Pearson JC, Daley DA, Le T, Robinson OJ, Gottlieb T et al. Molecular epidemiology of enterococcal bacteremia in Australia. *J Clin Microbiol*. 2014;52(3):897–905.
10. Clinical and Laboratory Standards Institute (CLSI). M100-S24 Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. Villanova, PA, USA, 2014.
11. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints – bacteria v 5.0. 2015. Available from: http://www.eucast.org/ast\_of\_bacteria/previous\_versions\_of\_documents/
12. Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. [Accessed: 03 Jun 2016]. Available from: https://github.com/tseemann/nullarbor
13. European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2018. [Internet.] European Centre for Disease Prevention and Control; 2019. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018
14. Coombs GW, Pearson JC, Daley DA, Le TT, Robinson JO, Gottlieb T et al. Australian Enterococcal Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. 2014;38(4):E320–6.
15. Coombs GW, Daley DA, Lee YT, Pang S, Pearson JC, Robinson JO et al. Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Programme annual report, 2014.Commun Dis Intell Q Rep. 2016;40(2):E236–43.
16. Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2015. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00015-5.
17. Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2016. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00020-9.
18. Geoffrey W Coombs GW, Denise A Daley DA, Yung Thin Lee YT, Dr Stanley Pang S. Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2017. Commun Dis Intell (2018). 2019;43. https://doi.org/10.33321/cdi.2019.43.42.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Cindy Toms

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**Communicable Diseases Intelligence is produced by:
Health Protection Policy Branch, Office of Health Protection, Australian Government Department of Health
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** cdi.editor@health.gov.au

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: cdi.editor@health.gov.au.

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2019 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.
<http://www.health.gov.au/cdna>